Olaratumab in combination with doxorubicin for treatment of advanced soft tissue sarcoma

An Evidence Review Group perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

Irina A. Tikhonova, Tracey Jones-Hughes , James Dunham, Fiona C. Warren, Sophie Robinson, Peter Stephens, Martin Hoyle

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The manufacturer of olaratumab (Lartruvo®), Eli Lilly & Company Limited, submitted evidence for the clinical and cost effectiveness of this drug, in combination with doxorubicin, for untreated advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy, as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal process. The Peninsula Technology Assessment Group, commissioned to act as the Evidence Review Group (ERG), critically reviewed the company’s submission. Clinical effectiveness evidence for the company’s analysis was derived from an open-label, randomised controlled trial, JGDG. The analysis was based on a partitioned survival model with a time horizon of 25 years, and the perspective was of the UK National Health Service (NHS) and Personal Social Services. Costs and benefits were discounted at 3.5% per year. Given the available evidence, olaratumab is likely to meet NICE’s end-of-life criteria. To improve the cost effectiveness of olaratumab, the company offered a discount through a Commercial Access Agreement (CAA) with the NHS England. When the discount was applied, the mean base-case and probabilistic incremental cost-effectiveness ratios (ICERs) for olaratumab plus doxorubicin versus the standard-of-care doxorubicin were £46,076 and £47,127 per quality-adjusted life-year (QALY) gained, respectively; the probability of this treatment being cost effective at the willingness-to-pay threshold of £50,000 per QALY gained, applicable to end-of-life treatments, was 0.54. The respective ICERs from the ERG’s analysis were approximately £60,000/QALY gained, and the probability of the treatment being cost effective was 0.21. In August 2017, the NICE Appraisal Committee recommended olaratumab in combination with doxorubicin for this indication for use via the UK Cancer Drugs Fund under the agreed CAA until further evidence being collected in the ongoing phase III trial—ANNOUNCE—becomes available in December 2020.
Original languageEnglish
Pages (from-to)39-49
Number of pages11
JournalPharmacoEconomics
Volume36
Issue number1
DOIs
Publication statusPublished - Jan 2018
Externally publishedYes

Fingerprint Dive into the research topics of 'Olaratumab in combination with doxorubicin for treatment of advanced soft tissue sarcoma: An Evidence Review Group perspective of a National Institute for Health and Care Excellence Single Technology Appraisal'. Together they form a unique fingerprint.

  • Cite this